The clinical relevance of Th17 cells is recently highlighted by the remarkable efficacy of anti-IL-17 antibodies in treating Psoriasis, Ankylosing spondylitis and Multiple sclerosis. Not all Th17 cells are pathogenic and in some autoimmune diseases (eg. IBD), anti-IL-17 antibodies made disease worse, highlighting the importance of selectively targeting pathogenic but spare protective Th17 cells. Costimulatory receptors and their ligands have a profound impact on autoimmune diseases by regulating the balance between pathogenic (Th1 and Th17) and protective (Treg) cell types. The role of inhibitory molecules in Th17 cell pathogenicity has not been fully explored. Using a temporal whole genome transcriptional approach, we have identified modules that positively or negatively regulate Th17 cell development as well as a signature that represents Th17 cells that can induce autoimmunity (pathogenic) and those that cannot (non-pathogenic). Among these molecules, a novel inhibitory molecule, PROCR (Protein C Receptor), emerged as selectively enriched on non-pathogenic Th17 cells. Similar to the well-known inhibitory molecule PD-1, PROCR can promote Th17 cell differentiation but once expressed inhibit effector functions of Th17 cells. We hypothesize that PROCR and PD-1 can influence the generation of pathogenic Th17 cells and thus regulate the development of autoimmune diseases. We propose these specific aims to address this hypothesis: 1: Study how PD-1 and PROCR regulate induction and effector functions of Th17 cells. Since both PD-1 and PROCR are co-inhibitory receptors, we propose that they do not only inhibit Th17 cells but also promote differentiation of non-pathogenic Th17 cells. Using PD-1-/- and PROCRd/d mice, we will analyze whether the two molecules synergize to affect Th17 development, function and whether they regulate the development of ectopic lymphoid follicles, a hallmark of Th17-induced chronic autoimmunity. 2: Determine the role of ligands of PROCR and PD-1 in limiting Th17 cell pathogenicity. Activated protein C (aPC), one of the known ligands for PROCR, has both anti-coagulant and anti-inflammatory effects. We have obtained a number of aPC mutants with selected functions and are beginning to test their ability to convert pathogenic Th17 cells into non-pathogenic Th17 cells and whether they synergize with PD-1 ligands to inhibit Th17 cell pathogenicity and alter clinical course of established autoimmune diseases. 3: Reconstruct the dynamic regulatory network to define the pathways by which PD-1 and PROCR control development and effector functions of Th17 cells. Since we have built a transcriptional network that controls development of Th17 cells, we are in a unique position to study how loss of PD-1 and PROCR will affect the network of Th17 cell differentiation and effector output. We will study how perturbation of key nodes in the PD-1 and PROCR pathway may change the Th17 cell fate and test their relevance using the EAE model.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
2P01AI056299-11
Application #
8742093
Study Section
Special Emphasis Panel (ZAI1)
Project Start
2014-09-01
Project End
2019-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
11
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Harvard Medical School
Department
Type
DUNS #
City
Boston
State
MA
Country
United States
Zip Code
02115
Xu, Jie; Sun, Heather H; Fletcher, Christopher D M et al. (2016) Expression of Programmed Cell Death 1 Ligands (PD-L1 and PD-L2) in Histiocytic and Dendritic Cell Disorders. Am J Surg Pathol 40:443-53
Borges, Christopher M; Reichenbach, Dawn K; Kim, Beom Seok et al. (2016) Regulatory T cell expressed MyD88 is critical for prolongation of allograft survival. Transpl Int 29:930-40
Chapuy, Bjoern; Roemer, Margaretha G M; Stewart, Chip et al. (2016) Targetable genetic features of primary testicular and primary central nervous system lymphomas. Blood 127:869-81
Schildberg, Frank A; Klein, Sarah R; Freeman, Gordon J et al. (2016) Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family. Immunity 44:955-72
Schönle, Anne; Hartl, Frederike A; Mentzel, Jan et al. (2016) Caveolin-1 regulates TCR signal strength and regulatory T-cell differentiation into alloreactive T cells. Blood 127:1930-9
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Zeiser, Robert; Blazar, Bruce R (2016) Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation? Blood 127:3117-26
Hirakawa, Masahiro; Matos, Tiago; Liu, Hongye et al. (2016) Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells. JCI Insight 1:e89278
Li, Wei; Liu, Liangyi; Gomez, Aurelie et al. (2016) Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease. JCI Insight 1:
Lo, Tsun-Ho; Silveira, Pablo A; Fromm, Phillip D et al. (2016) Characterization of the Expression and Function of the C-Type Lectin Receptor CD302 in Mice and Humans Reveals a Role in Dendritic Cell Migration. J Immunol 197:885-98

Showing the most recent 10 out of 257 publications